BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 15210894)

  • 1. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
    Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
    Neurology; 2004 Jun; 62(12):2277-82. PubMed ID: 15210894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
    Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
    Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis and Epstein-Barr virus.
    Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
    JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
    Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
    JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
    Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
    JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus and disease activity in multiple sclerosis.
    Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
    Nystad TW; Myrmel H
    J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
    Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
    J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
    Kvistad S; Myhr KM; Holmøy T; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Løken-Amsrud KI; Lilleås F; Midgard R; Njølstad G; Pedersen T; Benth JŠ; Wergeland S; Torkildsen O
    Mult Scler; 2014 Dec; 20(14):1833-40. PubMed ID: 24842958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
    Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
    Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients.
    Deeba E; Koptides D; Gaglia E; Constantinou A; Lambrianides A; Pantzaris M; Krashias G; Christodoulou C
    Mol Immunol; 2019 Jan; 105():270-275. PubMed ID: 30562647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.
    Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A
    J Med Virol; 2003 Aug; 70(4):617-23. PubMed ID: 12794726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
    Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
    J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
    Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
    Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus.
    Dickerson F; Jones-Brando L; Ford G; Genovese G; Stallings C; Origoni A; O'Dushlaine C; Katsafanas E; Sweeney K; Khushalani S; Yolken R
    Schizophr Bull; 2019 Sep; 45(5):1112-1119. PubMed ID: 30462333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
    Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
    PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up.
    DeLorenze GN; Munger KL; Lennette ET; Orentreich N; Vogelman JH; Ascherio A
    Arch Neurol; 2006 Jun; 63(6):839-44. PubMed ID: 16606758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
    Castellazzi M; Delbue S; Elia F; Gastaldi M; Franciotta D; Rizzo R; Bellini T; Bergamaschi R; Granieri E; Fainardi E
    Dis Markers; 2015; 2015():901312. PubMed ID: 26101453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
    Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
    J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
    Cortese M; Leng Y; Bjornevik K; Mitchell M; Healy BC; Mina MJ; Mancuso JD; Niebuhr DW; Munger KL; Elledge SJ; Ascherio A
    JAMA Neurol; 2024 May; 81(5):515-524. PubMed ID: 38497939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.